# Phase II Study to Evaluate the Effectiveness of EVT 302 in Smoking Cessation.

> **NCT00738595** · PHASE2 · COMPLETED · sponsor: **Evotec Neurosciences GmbH** · enrollment: 400 (estimated)

## Conditions studied

- Smoking Cessation

## Interventions

- **DRUG:** EVT 302
- **DRUG:** Placebo
- **DRUG:** EVT 302 plus open label Nicotine replacement
- **DRUG:** Placebo plus open label Nicotine Replacement

## Key facts

- **NCT ID:** NCT00738595
- **Lead sponsor:** Evotec Neurosciences GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-08
- **Primary completion:** 2009-03
- **Final completion:** 2009-05
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2009-05-29

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00738595

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00738595, "Phase II Study to Evaluate the Effectiveness of EVT 302 in Smoking Cessation.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00738595. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*